Daniel Rayson

5.2k total citations
137 papers, 3.4k citations indexed

About

Daniel Rayson is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel Rayson has authored 137 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 33 papers in Cancer Research and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel Rayson's work include HER2/EGFR in Cancer Research (32 papers), Breast Cancer Treatment Studies (31 papers) and Cancer Treatment and Pharmacology (24 papers). Daniel Rayson is often cited by papers focused on HER2/EGFR in Cancer Research (32 papers), Breast Cancer Treatment Studies (31 papers) and Cancer Treatment and Pharmacology (24 papers). Daniel Rayson collaborates with scholars based in Canada, United States and United Kingdom. Daniel Rayson's co-authors include Tallal Younis, Chris Skedgel, Penny J. Barnes, T. Younis, Stephen Chia, Lester E. Wold, Vera J. Suman, Karen A. Gelmon, Alex A. Adjei and Susan Dent and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Daniel Rayson

131 papers receiving 3.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Daniel Rayson 2.0k 885 524 463 452 137 3.4k
Ismail Jatoi 2.4k 1.2× 1.9k 2.1× 449 0.9× 267 0.6× 745 1.6× 141 4.5k
Andrea Veronesi 1.6k 0.8× 630 0.7× 676 1.3× 187 0.4× 286 0.6× 135 2.8k
D. Hölzel 2.0k 1.0× 671 0.8× 791 1.5× 134 0.3× 276 0.6× 126 3.2k
Adnan Ezzat 1.4k 0.7× 548 0.6× 667 1.3× 126 0.3× 722 1.6× 83 3.2k
Rachel A. Freedman 2.4k 1.2× 1.5k 1.7× 822 1.6× 128 0.3× 364 0.8× 186 4.0k
Sercan Aksoy 1.7k 0.9× 430 0.5× 780 1.5× 104 0.2× 334 0.7× 284 3.6k
Mikael Hartman 1.6k 0.8× 1.1k 1.3× 738 1.4× 97 0.2× 447 1.0× 149 3.6k
James Khatcheressian 1.9k 0.9× 858 1.0× 743 1.4× 130 0.3× 261 0.6× 24 2.8k
Donald R. Lannin 2.7k 1.3× 2.1k 2.3× 468 0.9× 135 0.3× 1.3k 2.8× 112 5.1k
Masashi Ando 2.0k 1.0× 774 0.9× 954 1.8× 112 0.2× 378 0.8× 206 3.6k

Countries citing papers authored by Daniel Rayson

Since Specialization
Citations

This map shows the geographic impact of Daniel Rayson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Rayson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Rayson more than expected).

Fields of papers citing papers by Daniel Rayson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Rayson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Rayson. The network helps show where Daniel Rayson may publish in the future.

Co-authorship network of co-authors of Daniel Rayson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Rayson. A scholar is included among the top collaborators of Daniel Rayson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Rayson. Daniel Rayson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Henning, Jan‐Willem, Christine Brezden‐Masley, Karen A. Gelmon, et al.. (2023). Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective. Current Oncology. 30(9). 8019–8038. 17 indexed citations
3.
Castonguay, Mathieu, et al.. (2022). HER2 testing in metastatic breast cancer – Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?. Annals of Diagnostic Pathology. 59. 151953–151953. 2 indexed citations
4.
Rayson, Daniel, Sonal Gandhi, Anil A. Joy, et al.. (2022). Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Current Oncology. 29(12). 9891–9895. 2 indexed citations
5.
Arnason, Thomas, et al.. (2021). Complete response of a colonic high-grade neuroendocrine carcinoma to platinum-based therapy: Insights from comprehensive genomic profiling. American Journal of Clinical Pathology. 156(Supplement_1). S143–S143. 2 indexed citations
6.
Bethune, Gillian, et al.. (2019). Isolated Tumor Cells in Sentinel Lymph Nodes of Primary Invasive Breast Carcinoma: A Cohort Analysis. Clinical Breast Cancer. 19(4). 286–291. 2 indexed citations
7.
Yan, Michael, Cheryl Ho, Eric Winquist, et al.. (2016). Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid. Clinical Colorectal Cancer. 15(4). 369–376.e3. 7 indexed citations
8.
Broglio, Kristine, Melanie Quintana, Margaret Foster, et al.. (2016). Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes. JAMA Oncology. 2(6). 751–751. 229 indexed citations
9.
10.
Skedgel, Chris, et al.. (2015). Cost–Utility of Adjuvant Zoledronic Acid in Patients with Breast Cancer and Low Estrogen Levels. Current Oncology. 22(4). 246–253.
11.
12.
Singh, Simron, Hagen F. Kennecke, Walter Kocha, et al.. (2014). Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Annals of Surgical Oncology. 22(8). 2685–2699. 65 indexed citations
13.
Steensma, David P., Daniel Rayson, Marc A. Shampo, & Robert A. Kyle. (2014). Terry Fox: Canadian Cancer Research Activist Whose “Marathon of Hope” Inspired Millions. Mayo Clinic Proceedings. 89(8). e75–e76. 3 indexed citations
14.
Skedgel, Chris, Daniel Rayson, & T. Younis. (2013). Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?. Annals of Oncology. 24(7). 1834–1840. 10 indexed citations
15.
Verma, Sunil, Anil A. Joy, Daniel Rayson, et al.. (2013). HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer. The Oncologist. 18(11). 1153–1166. 11 indexed citations
16.
Arnason, Thomas, et al.. (2011). Immunohistochemical Expression and Prognostic Value of ER, PR and HER2/neu in Pancreatic and Small Intestinal Neuroendocrine Tumors. Neuroendocrinology. 93(4). 249–258. 30 indexed citations
17.
Rayson, Daniel, Thomas Suter, Christian Jackisch, et al.. (2011). Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Annals of Oncology. 23(7). 1780–1788. 33 indexed citations
18.
Lavasani, Sayeh, John R. Mackey, Kathleen I. Pritchard, et al.. (2010). Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality. Current Oncology. 17(4). 20–33. 23 indexed citations
19.
Rayson, Daniel, D. J. Richel, Stephen Chia, et al.. (2008). Anthracycline–trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Annals of Oncology. 19(9). 1530–1539. 73 indexed citations
20.
Rayson, Daniel, et al.. (1999). Scleromyxedema: A Complete Response to Prednisone. Mayo Clinic Proceedings. 74(5). 481–484. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ismail Jatoi Breakdown of academic impact, for papers by Andrea Veronesi Breakdown of academic impact, for papers by D. Hölzel Breakdown of academic impact, for papers by Adnan Ezzat Breakdown of academic impact, for papers by Rachel A. Freedman Breakdown of academic impact, for papers by Sercan Aksoy Breakdown of academic impact, for papers by Mikael Hartman Breakdown of academic impact, for papers by James Khatcheressian Breakdown of academic impact, for papers by Donald R. Lannin Breakdown of academic impact, for papers by Masashi Ando
Rankless by CCL
2026